SSA+, n = 14 | SSA-, n = 9 | Total, n = 23 | P | |
---|---|---|---|---|
Age, yrs, median [range] | 41.6 [15–65] | 46.9 [30–59] | 43.7 [15–65] | 0.29 |
Sex, female | 13 (93) | 9 (100) | 22 (96) | > 0.99 |
Familial history | ||||
Autoimmune disease | 2 (14) | 1 (11) | 3 (13) | > 0.99 |
SpA, IBD, and/or PsO | 5 (36) | 4 (44) | 9 (39) | > 0.99 |
Clinical characteristics of pSS | ||||
Eye dryness | 12 (86) | 9 (100) | 21 (91) | 0.50 |
Mouth dryness | 13 (93) | 9 (100) | 22 (96) | > 0.99 |
Dryness complication | 4 (29) | 5 (56) | 9 (39) | 0.38 |
Extraarticular/extraglandular manifestations | 5 (36) | 4 (44) | 9 (39) | 0.55 |
Peripheral articular manifestations | ||||
Arthralgia | 14 (100) | 9 (100) | 23 (100) | > 0.99 |
Arthritis | 12 (86) | 8 (89) | 20 (87) | > 0.99 |
Heel enthesitis | 9 (64) | 8 (89) | 17 (74) | 0.34 |
Dactylitis | 1 (7) | 1 (11) | 2 (9) | > 0.99 |
Axial articular manifestations | ||||
Inflammatory back pain | 12 (86) | 6 (67) | 18 (78) | 0.34 |
Sacroiliac pain | 12 (86) | 9 (100) | 21 (91) | 0.50 |
Chest pain | 4 (29) | 4 (44) | 8 (35) | 0.66 |
Type of SpA | ||||
AS | 2 (14) | 4 (44) | 6 (26) | 0.16 |
PsA | 12 (86) | 5 (56) | 17 (74) | 0.16 |
Radiographic abnormalities | ||||
Sacroiliitis | 9 (64) | 6 (67) | 15 (65) | > 0.99 |
Spine lesion | 4 (29) | 2 (22) | 6 (26) | > 0.99 |
Immunological data | ||||
ANA titer ≥ 160 | 13 (93) | 7 (78) | 20 (87) | 0.54 |
ANA titer, mean [range] | 788 [160–1280] | 400 [160–1280] | 652 [160–1280] | 0.08 |
Low complement fractions | 2 (14) | 0 (0) | 2 (9) | 0.50 |
Hypergammaglobulinemia | 9 (64) | 2 (22) | 11 (48) | 0.09 |
Positive RF | 5 (36) | 1 (11) | 6 (26) | 0.34 |
Cryoglobulinemia | 2/8 (25) | 0 (0) | 2/13 (15) | 0.47 |
Focal sialadenitis and FS ≥ 1 | 3/11 (27) | 9/9 (100) | 12/20 (60) | 0.001* |
HLA-B27 | 0/14 (0) | 3/9 (33) | 3/23 (13) | 0.02* |
Treatment | ||||
HCQ | 10 (71) | 7 (78) | 17 (74) | > 0.99 |
NSAID | 7 (50) | 6 (67) | 13 (57) | 0.67 |
CS | 7 (50) | 4 (44) | 11 (48) | > 0.99 |
DMARD | 9 (64) | 7 (78) | 16 (70) | 0.66 |
Biotherapy | ||||
Anti-TNF | 7 (50) | 6 (67) | 13 (57) | 0.67 |
Secukinumab | 3 (21) | 3 (33) | 6 (26) | 0.64 |
Other | 1 (7) | 3 (33) | 4 (17) | 0.26 |
Values are expressed as n (%) unless stated otherwise.
↵*P < 0.05. ANA: antinuclear antibody; AS: ankylosing spondylitis; CS: corticosteroids; DMARD: disease-modifying antirheumatic drugs; FS: focus score; HCQ: hydroxychloroquine; IBD: inflammatory bowel disease; NSAID: nonsteroidal anti-inflammatory drug; PsA: psoriatic arthritis; PsO: psoriasis; pSS: primary Sjögren syndrome; RF: rheumatoid factor; SpA: spondyloarthritis; TNF: tumor necrosis factor.